Real world experience in the era of first generation protease inhibitors in the treatment of hepatitis C

被引：0

作者：

Hubbard H. ^{[1
]}

Lawitz E. ^{[2
]}

机构：

[1] Division of Gastroenterology, University of Texas Health Science Center San Antonio, Mail Code 7878, San Antonio, TX 78229

[2] Texas Liver Institute, University of Texas Health Science Center San Antonio, San Antonio, TX 78215

来源：

Current Hepatitis Reports | 2013年 / 12卷 / 4期

关键词：

Acting; Antivirals; Boceprevir; Direct; Experience; Hepatitis c; Inhibitors; Protease; Real; Telaprevir; Treatment; World;

D O I：

10.1007/s11901-013-0189-z

中图分类号：

学科分类号：

摘要：

The treatment for hepatitis C has been revolutionized with the new era of protease inhibitors. Boceprevir (BOC) and telaprevir (TVR) are potent first generation direct acting antivirals which have demonstrated significantly improved response rates compared to interferon and ribavirin in phase III trials. However there are multiple real-life data sets showing increased adverse events and treatment discontinuations compared to clinical trials, especially in the cirrhotic patient. The advent of all oral, non-interferon regimens offers a promising treatment paradigm for hepatitis C infected patients. © 2013 Springer Science+Business Media New York.

引用

页码：189 / 194

页数：5

共 35 条

[1]

Jacobson I.M., McHutchison J.G., Dusheiko G., Et al., Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, pp. 2405-2416, (2011)

[2]

Kwo P.Y., Lawitz E.J., McCone J., Et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): An open label, randomized, multicentre phase 2 trial, Lancet, 376, pp. 705-716, (2010)

[3]

Yee H.S., Chang M.E., Pocha C., Et al., Update on the management and treatment of hepatitis C virus infection: Recommendations from the department of veterans affairs Hepatitis C resource center program and the national Hepatitis C program office, Am J Gastroenterol, 107, pp. 669-689, (2012)

[4]

McHutchison J.G., Lawitz E.J., Shiffman M.L., Et al., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N Engl J Med, 361, pp. 580-593, (2009)

[5]

Sherman K.E., Flamm S.L., Afdhal N.H., Et al., Response-guided telaprevir combination treatment for hepatitis C virus infection, N Engl J Med, 365, pp. 1014-1024, (2011)

[6]

Poordad F., McCone J., Bacon B.R., Et al., Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, pp. 1195-1206, (2011)

[7]

Forestier N., Zeuzem S., Triple therapy with telaprevir: Results in hepatitis C virus-genotype 1 infected relapsers and non-responders, Liver Int, 32, SUPPL. 1, pp. 44-50, (2012)

[8]

Bacon B., Khalid O., Triple therapy with boceprevir for HCV genotype 1 infection: Phase III results in relapsers and nonresponders, Liver Int, 32, SUPPL. 1, pp. 51-53, (2012)

[9]

Bacon B.R., Gordon S.C., Lawitz E., Et al., Boceprevir for previously untreated chronic HCV genotype 1 infection, N Engl J Med, 364, pp. 1207-1217, (2011)

[10]

Hezode C., Dorival C., Zoulim F., Et al., Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC), J Hepatol, 56, SUPPL., (2012)

← 1 2 3 4 →